"I believe that this could have been prevented by more vigilance," Siegel said.
However, he added that he doesn't expect the number of infected patients to balloon in the near future.
"This is not going to be an epidemic, because the fungus is weak and there isn't a reservoir," Siegel said. "But there will continue to be isolated cases over the next several weeks because of the long incubation period."
Specialty manufacturers like New England Compounding Center make solutions that aren't available from the big pharmaceutical companies, but they aren't subject to the same rigorous safety standards, such as FDA oversight.
The U.S. National Library of Medicine has more about injections for back pain.
Copyright © 2012 HealthDay. All rights reserved.